IAFF Launches Smoking Cessation Campaign with Pfizer

Pfizer Inc.The International Association of Fire Fighters has announced the launch of a new initiative to help fire fighters, family members and friends to quit smoking cigarettes. "Our goal is to help make the IAFF the first smoke-free union," IAFF General President Harold Schaitberger said in his address to delegates at the IAFF 49th Convention.

The IAFF is collaborating with pharmaceutical company Pfizer Inc. to promote smoking cessation. Schaitberger and Pfizer CEO Jeff Kindler first announced the joint initiative at the IAFF Health and Safety Conference in Chicago, Illinois, in October 2007.

The campaign includes materials designed to help fire fighters understand the risks of smoking and provide information on how to quit. These and other resources are available on a new web site at www.iaff.org/smokefree. In the coming weeks, the campaign will add new resources, including a DVD featuring stories from fire fighters about how they quit smoking. The web site and other materials are available to assist IAFF affiliates across North America in reaching out to members, families and communities to promote and encourage smoking cessation.

Smoking is a major health risk for fire fighters who are already at high risk for illnesses, including heart disease, respiratory disease and certain cancers. In addition, smoking is the leading cause of fires and a significant occupational risk for fire fighters.

"We congratulate the IAFF for its commitment to this campaign and look forward to working together toward the goal of a smoke-free union," Kindler said. "Fire fighters are respected leaders in their communities, and this program on smoking cessation reaffirms that leadership."

"Fire fighters place themselves in harm's way, confront dangerous environments, high heat and flames, and exposure to burning materials," Schaitberger said. "It's stressful work and some respond to stress by smoking. Yet smoking increases the health risks fire fighters face. We want to help prevent that."

The International Association of Fire Fighters, headquartered in Washington, DC, represents more than 288,000 full-time professional fire fighters and paramedics who protect 85 percent of the nation's population. More information is available at www.iaff.org.

Pfizer discovers and develops innovative medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality healthcare and health system support.

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...

Sinovac receives conditional marketing authorizati…

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Produ...